MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. -Scientific Presentations Showcase InnovativeMS Medicines and Experimental Therapies- CAMBRIDGE, Mass. --(BUSINESS WIRE)-- 30.05.2014 -- Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions. Data are being presented during the annual meeting of the Consortium of Multiple Sclerosis Centers (CMSC) and the Sixth Cooperative Meeting with Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS; May 28 May 31 in Dallas, Texas); and the Joint Congress of the European Federation of Neurological Societies (EFNS) and European Neurological Society (ENS; May 31 June 3 in Istanbul, Turkey). Our research and development efforts over the past 30 years have positioned Biogen Idec at the forefront of MS innovation, and the scope of data we are presenting at CMSC/ACTRIMS and EFNS/ENS underscores our commitment to improving the lives of people living with MS, said Katherine Dawson, M.D., vice president, global … Continue reading →

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. European Commission Decision on Marketing Authorization Anticipated in 2H of 2014 PLEGRIDY May Offer People with MS a Combination of Efficacy, Favorable Safety Profile and Low Frequency Dosing Schedule CAMBRIDGE, Mass. --(BUSINESS WIRE)-- 23.05.2014 -- Biogen Idec (NASDAQ: BIIB) today received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the marketing authorization of PLEGRIDY (peginterferon beta-1a), a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS). The CHMPs positive opinion is now referred to the European Commission (EC), which grants marketing authorization for medicines in the EU. The CHMPs positive opinion for PLEGRIDY marks an important milestone in bringing a meaningful treatment advance to people with MS in the EU, said Douglas E. Williams, Ph.D., Biogen Idecs executive vice president of Research and Development. We believe PLEGRIDY will offer physicians and those living with MS a unique treatment option that combines efficacy, a favorable safety profile consistent with the established interferon class, and a once-every-two-week dosing schedule. The CHMP opinion is primarily based on Phase 3 data from ADVANCE, one of the … Continue reading →

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. Additional Real-World Data Show Tolerability Profile Consistent with Pivotal Studies CAMBRIDGE, Mass. --(BUSINESS WIRE)-- 30.04.2014 -- New data reinforce the efficacy of TECFIDERA in a wide range of patients with relapsing-remitting multiple sclerosis (RRMS), as well as support its favorable safety and tolerability profile in the real-world setting. These data were presented by Biogen Idec (NASDAQ: BIIB) at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia. A new post-hoc analysis from the Phase 3 studies, DEFINE and CONFIRM, reinforce that TECFIDERA can be effective in RRMS patients with high disease activity. In addition, new data from the Phase 4 MANAGE study show that gastrointestinal (GI) events experienced by patients in the clinical practice setting were mostly mild to moderate and generally manageable, and significantly decreased in prevalence within the first two months of TECFIDERA treatment. These new data further reinforce the benefits TECFIDERAs strong efficacy may bring to a wide range of people with relapsing forms of multiple sclerosis (MS), said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen Idec. In addition, as we gain even more … Continue reading →

Joan Hendry A teenager who allegedly stabbed his mother to death in White Gum Valley on Monday night may have had a psychotic episode after earlier seeking hospital treatment. The major crime squad is investigating the death of Joan Hendry, 52, who died after an apparent frenzied incident at her Stevens Street house just after 11.30pm. Ms Hendry's 19-year-old son Gabe Lang is in hospital with critical injuries from what are believed to be self-inflicted knife wounds. "We saw him come out and fall into a car bonnet with what looked like a stab wound on his neck," one neighbour said. Several neighbours said they heard screams coming from the house before the sound of sirens. Ms Hendry's partner Bruce Abbott and her daughter Rosie Lang were also injured in the incident that left a community bewildered and heartbroken. "It is such a tragedy and will be a big loss," Frank Sander, Ms Hendry's friend of more than 20 years, said. "People are looking for answers. "We called her Joanie the one and only - she was a very exquisite woman." More here: Killed mother sought help for son … Continue reading →

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH. Additional Data Show Escalation to TYSABRI Following Relapse Improves Clinical Outcomes Compared to Remaining On or Switching Between First-Line Interferon Beta and Glatiramer Acetate CAMBRIDGE, Mass. --(BUSINESS WIRE)-- 01.05.2014 -- Biogen Idec(NASDAQ: BIIB) today announced that a post hoc analysis of data from the AFFIRM study shows TYSABRI (natalizumab) significantly increased the proportion of relapsing-remitting multiple sclerosis (RRMS) patients with confirmed improvement in walking speed (CIWS) relative to placebo at two years. Additional data from observational registry studies show that switching to TYSABRI after experiencing a multiple sclerosis (MS) relapse while taking interferon beta (IFN) or glatiramer acetate (GA) reduced the risk of future relapses and treatment discontinuation. These data were presented at the 66th American Academy of Neurology (AAN) annual meeting in Philadelphia, Pa. (April 26-May 3, 2014). We know that MS has a significant impact on ambulation a key concern for many people living with this disease which is why we analyzed data from AFFIRM to evaluate the potential impact of TYSABRI on walking speed, said Alfred Sandrock, M.D., Ph.D., group senior vice president and chief medical officer at Biogen Idec. TYSABRI was associated … Continue reading →